Dr. Daniel Johnson, D.O.
Family Medicine (Family Medicine Physician)
3250 Fordham St
San Diego, CA 92110
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
At a glance
- Medical school
- Arizona College of Osteopathic Medicine Mid Western University (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2006
Licensed in California since 2005, according to the Osteopathic Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Arizona College of Osteopathic Medicine Mid Western University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
CA license 20A9393 (first issued 2005; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Medical Center Acute New Orleans, LA
Medical groups
- Southern California Permanente Medical Group (11,293 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 3 companies. The companies reported $1,592,679 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
ModernaTX, Inc. · Completed · NCT06864143 - A phase 12 randomized doubleblinded study to evaluate the safety tolerability and immunogenicity of modified rna vaccine candidates against influenza and COVID19 in healthy individuals
Pfizer Inc. - Study name not reported
Roche Molecular Systems, Inc. - A phase 3 study to evaluate the efficacy immunogenicity and safety of respiratory syncytial virus rsv prefusion f subunit vaccine in adults
Pfizer Inc. - A phase 3 randomized observerblinded study to evaluate the safety tolerability and immunogenicity of a combined modified rna vaccine candidate against COVID19 and influenza in healthy individuals
Pfizer Inc. - A phase 3 randomized observerblinded study to evaluate the efficacy safety tolerability and immunogenicity of a modified rna vaccine against influenza compared to licensed inactivated influenza vaccine in healthy adul…
Pfizer Inc. - A phase 3 multicenter parallelgroup openlabel study to evaluate the safety tolerability and immunogenicity of respiratory syncytial virus prefusion f subunit vaccine when coadministered with herpes zoster subunit vacc…
Pfizer Inc. - A phase 12 randomized observerblinded study to evaluate the safety tolerability and immunogenicity of combined vaccine candidates against influenza and COVID19 in healthy individuals
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.